ERBB2 and neoplasm: Therapy results showed that HER2-trageted Herceptin and Lapatinib did not show any inhibitive role in SH3BGRL and HER2 doubly positive tumors, but AKT inhibitors LY294002 showed the evident inhibition to this doubly positive type tumor progression.